Physician profile
Robert E Tepper
NPI 1023013570
$2,822.53
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,588 · 2020: $237 · 2021: $153 · 2022: $594 · 2023: $125 · 2024: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $929.93 | 2019-2023 | Skyrizi |
| Janssen Biotech, INC. | $367.27 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $230.96 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $182.58 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $172.19 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.15 | 2019-2022 | |
| Pfizer INC. | $128.46 | 2019 | |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $125.00 | 2024 | |
| Ucb, INC. | $80.12 | 2019-2020 | |
| Redhill Biopharma INC. | $73.96 | 2022 | |
| Celgene Corporation | $71.01 | 2022 | |
| Ferring Pharmaceuticals INC. | $64.53 | 2019 | |
| Daiichi Sankyo INC. | $36.92 | 2019-2022 | |
| Braintree Laboratories, INC. | $28.61 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $19.08 | 2022 | |
| Ardelyx, INC. | $15.24 | 2022 | |
| Ironwood Pharmaceuticals, INC | $13.52 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.